Dec 13, 2022
S1 EP5: The use of SGLT2 inhibitors in patients hospitalised for acute heart failure
*Episode 5 - The use of SGLT2 inhibitors in patients hospitalised for acute heart failure - Prof. Christiane Angermann*
We are joined by Professor Christiane Angermann. Prof Angermann is a Senior Professor of Medicine and Clinical Research in Cardiology at the University and University Hospital Würzburg in Germany, and co-founder of the Comprehensive Heart Failure Centre Würzburg (CHFC). She acted as coordinating investigator in the Executive Committee of the EMPULSE trial, a multinational clinical trial evaluating the clinical benefit of empagliflozin in patients who were stabilised after hospitalisation for acute heart failure. She has published over 240 peer-reviewed articles and is currently editor-in-chief for Current Heart Failure Reports.
For this episode, we will explore the potential for the use of empagliflozin in patients who are hospitalised with heart failure.
Voors, AA, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat. Med., 2022; 28,: 568–574. https://doi.org/10.1038/s41591-021-01659-1
Biegus, J, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial, European Heart Journal, 2022; ehac530, https://doi.org/10.1093/eurheartj/ehac530
Mebazaa, A, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.
Lancet. 2022; 400: 1938–1952. https://doi.org/10.1016/S0140-6736(22)02076-1* *
Voors, AA, et al. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation 2022; 146: 279–288. https://doi.org/10.1161/CIRCULATIONAHA.122.059725
Emmens, JE, et al. Worsening renal function in acute heart failure in the context of diuretic response. Eur J Heart Fail. 2022; 24: 365-374. https://doi.org/10.1002/ejhf.2384
*“This series of medical educational podcasts and associated materials have been sponsored by Boehringer Ingelheim and Lilly Alliance (The Alliance). The Alliance had no influence over the agenda, programme development, content or selection of the faculty. Editorial and content decisions were made solely by Oruen Limited, and faculty chosen by Oruen Limited”. *
*“Not intended for US & UK based healthcare professionals”.*